Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating
Leerink Partners Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Maintains Target Price $49
Citi Upgrades Kymera Therapeutics(KYMR.US) to Buy Rating, Raises Target Price to $52
Kymera Therapeutics Analyst Ratings
Citigroup Initiates Coverage on Kymera Therapeutics With Buy Rating, $52 Price Target
TD Cowen Maintains Kymera Therapeutics(KYMR.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Kymera Therapeutics (KYMR) and Anika Therapeutics (ANIK)
Leerink Partners Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $60
Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Cuts Target Price to $51
Stifel Nicolaus Sticks to Their Buy Rating for Kymera Therapeutics (KYMR)
A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $53 to $72
Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Dyne Therapeutics (DYN) and Kymera Therapeutics (KYMR)
A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $54 to $57
Kymera Therapeutics Analyst Ratings
Kymera Therapeutics (KYMR) Receives a Buy From TD Cowen
Kymera Therapeutics Analyst Ratings
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Maintains Target Price $49
BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Raises Target Price to $50
Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating